A rising percentage of parents say they won't have their teen daughters vaccinated to protect against the human papilloma virus, even though physicians are increasingly recommending adolescent vaccinations, a study by Mayo Clinic and others shows. More than 2 in 5 parents surveyed believe the HPV vaccine is unnecessary, and a growing number worry about potential side effects, researchers found. The findings are published in the new issue of the journal Pediatrics.
In all, researchers looked at three vaccines routinely recommended for U.S. teens: a vaccine to protect against the sexually transmitted HPV; Tdap, for tetanus, diphtheria and acellular pertussis; and the meningococcal conjugate vaccine, or MCV4 vaccine. While the up-to-date immunization rates rose for all three vaccines, the proportion of girls fully immunized against HPV (three doses over six months) was substantially lower than the proportion for the other two vaccines.
Five years ago, 40 percent of parents surveyed said they wouldn't vaccinate their girls against HPV. In 2009, that rose to 41 percent, and in 2010, to 44 percent.
"That's the opposite direction that rate should be going," says senior researcher Robert Jacobson, M.D., a pediatrician with the Mayo Clinic Children's Center.
Parents concerned about HPV vaccine safety rose from 5 percent in 2008 to 16 percent in 2010, while less than 1 percent worried about the safety of the Tdap and MCV4 vaccines, the study found.
During the same years, more and more studies showed how safe and effective the HPV vaccine is in this age group, says Dr. Jacobson, who has taken part in the safety review committees for two such studies. The vaccine prevents cervical cancer and other genital cancers by preventing the HPV infections that lead to those cancers, he says.
Researchers analyzed vaccination data for teens ages 13 to 17 in the 2008-10 National Immunization Survey of Teens. They found that as of 2010, 8 of 10 teens had the Tdap vaccine and roughly 63 percent had the MCV4 vaccine. Only about one-third of girls were immunized against HPV.
The HPV vaccination rate did rise; it was only 16 percent in 2008. But at the same time, more parents reported that they did not intend to have their daughters vaccinated for HPV. Among the reasons they gave: the vaccine was not recommended; lack of knowledge; it is unnecessary; the vaccine is inappropriate for the child's age; worry about safety/side effects; and the child isn't sexually active.
According to parents surveyed, more clinicians are recommending the HPV vaccine, but still, they are advising it only about half the time. The facts show the vaccine is necessary, Dr. Jacobson says.
"HPV causes essentially 100 percent of cervical cancer and 50 percent of all Americans get infected at least once with HPV. It's a silent infection. You cannot tell when you've been exposed or when you have it," he says. "While most HPV infections clear, a percentage linger and start the process of cancerous changes. The HPV vaccine is an anti-cancer vaccine."
Dr. Jacobson says the vaccine is more effective in younger adolescents than older teens. Mayo Clinic routinely starts the series at age 9.
"The vaccine works better the younger the child is, and it doesn't work after the child is grown up and is exposed to the virus, so our message should be: 'Give this vaccine now to your child while your child is young and responsive to it,'" says Dr. Jacobson, medical director of the Employee and Community Health Immunization Program at Mayo Clinic.
Study co-authors include Paul Darden, M.D., David Thompson, Ph.D., Jessica Hale, and Monique Naifeh, M.D., M.P.H., University of Oklahoma; and James Roberts, M.D., M.P.H., and Charlene Pope, Medical University of South Carolina.The study was supported by grant R40 MC 21522 through the U.S. Department of Health and Human Services' Maternal and Child Health Research Program. Dr. Darden has consulted and advised Pfizer Inc. Dr Jacobson has served as principal investigator for two multicenter vaccine studies funded by Pfizer, one funded by Novartis, all at Mayo Clinic. He is on a safety review committee for one vaccine study and on a data and safety monitoring board for two other vaccine studies, all funded by Merck.
Robert Nellis | EurekAlert!
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
23.08.2017 | Life Sciences
23.08.2017 | Life Sciences
23.08.2017 | Physics and Astronomy